Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00472927 · ClinicalTrials.gov registry record · Phase 1
Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)
A Phase 1 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00472927 is a Phase 1 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer.
The verdict
NCT00472927, a Phase 1 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
Interventions
- DRUG Premarin/MPA 0.45 mg/1.5 mg
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00472927
The ClinicalTrials.gov registry entry for NCT00472927 describes a study currently listed as completed, categorized as Phase 1. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Premarin/MPA 0.45 mg/1.5 mg is the first listed.
NCT00472927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00472927 about?
NCT00472927 is a clinical study titled "Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)". To evaluate three new investigational tablet formulations of the Food and Drug Administration (FDA) approved medication Prempro™, Premarin combined with medroxyprogesterone acetate (MPA).
What is the current status of trial NCT00472927?
This trial is currently completed. It is a Phase 1 study. The study started on 2007-05. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00472927?
The interventions under investigation include: Premarin/MPA 0.45 mg/1.5 mg (DRUG).
Who is sponsoring clinical trial NCT00472927?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.